About Us

​NACHO was formed in July 2014 by clinicians and scientists from twelve institutions dedicated to developing a research infrastructure to effectively implement clinical and translational studies and conduct biological research of histiocytic diseases. 

Mission

Our mission is to cure all patients with histiocytic diseases and optimize outcomes through innovative and collaborative research.

Goals

  • To develop a network for the advancement of clinical, translational, and basic research in histiocytic diseases.
  • To advance therapeutic, etiological and mechanistic research through the implementation of high impact clinical trials and organized collection of well annotated clinical data and biology specimens.
  • To define the pathogenesis of histiocytic diseases and develop risk-stratification strategies with tissue samples from patients treated on NACHO trials.

Consortium Principle Investigators

​Carlos Rodriguez-Galindo, MD
  • Consortium Principal Investigator
  • Director, NACHO Operations Center 
  • St. Jude Children’s Research Hospital  
    • Member, St. Jude Faculty
    • ​Executive Vice President
    • Chair, Department of Global Pediatric Medicine
    • Director, St. Jude Global
    • Co-Associate Director, Outreach, Comprehensive Cancer Center
Carl Allen, MD, PhD
  • Consortium Co-Principal Investigator
  • Director, NACHO Biology Center 
  • Texas Children’s Cancer Center
    • Histiocytosis Program Co-Director
    • Lymphoma Program Co-Director
    • Director of Research, Global Hematology-Oncology Pediatric Excellence (HOPE)
  • Baylor College of Medicine
    • Professor, Department of Pediatrics, Hematology-Oncology, Baylor College of Medicine

Learn More About Us

NACHO brings multiple institutions and people together. Learn more about this unique consortium!​​​​